Qualitative and quantitative analysis of antibody response against IFNβ in patients with multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 6, 2006, Pages 738-746

  Gilli, Francesca ^a   Hoffmann, F ^b   Sala, A ^a   Marnetto, F ^a   Caladno, M ^a   Valentino, P ^a   Kappos, L ^b   Bertolotto, A ^a   Lindberg, R L P ^b  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Binding antibodies; ELISA; IFN ; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

BETA1A INTERFERON; INTERFERON ANTIBODY; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON;

ANTIBODY RESPONSE; ANTIBODY SCREENING; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING ASSAY; BLOOD SAMPLING; CONSTANTS AND COEFFICIENTS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KAPPA STATISTICS; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; CELL LINE, TUMOR; ENCEPHALOMYOCARDITIS VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOASSAY; INTERFERON-BETA; LUNG NEOPLASMS; MASS SCREENING; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; REPRODUCIBILITY OF RESULTS;

EID: 33846276576     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070968     Document Type: Article

References (38)

1. The EFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
3. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, the University of British Columbia MS/MRI Analysis Group. PRISMS-4: longterm efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36.
4. Vallbracht A, Treuner J, Flehmig B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 1981; 5: 496-97.
5. Rudick RA, Ransohoff RM, Lee JC, Peppler R, Yu M, Mathisen PM et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-300.
6. Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C et al. Neutralizing antibodies during treatment of secondary progressive multiple sclerosis with interferon β-1b. Neurology 2003; 60: 37-43.
7. Perini P, Calabrese M, Biasi G, Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004; 251: 305-309.
8. Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004; 62: 2031-37.
9. Giovannoni G, Munschauer FE III, Deisenhammer F. Neutralizing antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 465-69.
10. Bertolotto A. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 2004; 17: 241-46.
11. Ross C, Clemmesen EM, Sørensen PS, Koch-Henriksen, Bendtzen K. Measuring and evaluating interferon β-induced antibodies in patients with multiple sclerosis. Mult Scler 2006; 12: 39-46.
12. Benoit P, Maguire D, Plavec I, Kocher H, Tovey M, Meyer F. A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, IFN-omega. Detection of eterogeneity of the cellular type I receptor. Immunology 1993; 1: 707-16.
13. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266-72.
14. Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β. J Immunol Methods 1999; 227: 121-35.
15. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-β antibodies in MS patients. Neurology 2003; 61: 1444-46.
16. Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 1999; 10: 413-22.
17. Perini P, Facchinetti A, Bullan P, Massaro AN, Pascalis DD, Bertolotto A et al. Interferon-beta (IFN-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12: 56-61.
18. Scagnolari. C, Bellomi F, Turriziani O, Bagnato F, Tommasini V, Lavolpe V et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interferon Cytokine Res 2002; 22: 207-13.
19. Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003; 15: 3-8.
20. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Correnti M et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-b1a. J Interferon Cytokine Res 1998; 18: 345-50.
21. WHO Expert Committee on Biological Standardisation. Thirty-Fifth Report. WHO Technical Report Series 725. World Health Organization, 1985.
22. Kawade Y, Finter N, Grossberg SE. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods 2003; 278: 127-44.
23. Kawade Y. Quantitation of neutralization of interferon by antibody. Meth Enzymol 1986; 119: 558-73.
24. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21: 743-55.
25. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986; 2: 307-10.
26. Chan YH. Biostatistics 104: correlation analysis. Singapore Med J 2003; 44: 614-19.
27. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003; 228: 303-308.
28. Landis JR, Koch GG. The measurement of observed agreement for categorical data. Biometrics 1977; 33: 159-74.
29. Herndon RM, Rudick RA, Munschaner FE III, Mass MK, Salazar AM, Coats ME et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005; 11: 409-19.
30. Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 2004; 26: 511-21.
31. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
32. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon β-1b in MS patients are cross-reactive. Neurology 1998; 51: 1698-702.
33. Deisenhammer F, Reindel M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239-43.
34. Bertolotto A, Gilli F, Sala A. Capobianco M, Malucchi S, Milano E et al. Persistent neutralizing antibodies abolish the interferon-β bioavailability in MS patients. Neurology 2003; 60: 634-39.
35. Pachner AR, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-β bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7: 17-25.
36. Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S et al. Neutralising antibodies against IFN-β in MS: antagonisation of IFN-β mediated suppression of MMPs. Brain 2004; 127: 259-68.
37. Pungor E, Files JG, Gabe JD, Do LT, Foley WP, Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J Interferon Cytokine Res 1998; 18: 1025-30.
38. Lampasona V, Rio J, Franciotta D, Furlan R, Avolio C, Fazio R et al. Serial immunoprecipitation assays for interferon - (IFN)-beta antibodies in multiple sclerosis patients. Eur Cytokine Netw 2003; 14: 154-57.